ReviewGene therapy2012
Vein graft failure: current clinical practice and potential for gene therapeutics.
Review in Gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Comparative evaluation of cell types for endothelialization in cardiovascular tissue engineering.Iranian journal of basic medical sciences · 2026Review
- Techniques and Technologies to Improve Vein Graft Patency in Coronary Surgery.Medical sciences (Basel, Switzerland) · 2024Review
- Consensus statement-graft treatment in cardiovascular bypass graft surgery.Frontiers in cardiovascular medicine · 2024Article
- Inhibition of Intimal Thickening By PRH (Proline-Rich Homeodomain) in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- In Vitro Differentiation of Myoblast Cell Lines on Spider Silk Scaffolds in a Rotating Bioreactor for Vascular Tissue Engineering.Journal of personalized medicine · 2022Article
- The Role of Endothelial Cells in the Onset, Development and Modulation of Vein Graft Disease.Cells · 2022Review
- Systematic review on the application of 3D-bioprinting technology in orthoregeneration: current achievements and open challenges.Journal of experimental orthopaedics · 2022Review
- Saphenous Vein Vasa Vasorum as a Potential Target for Perivascular Fat-Derived Factors.Brazilian journal of cardiovascular surgery · 2020Review
- Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2019Review
- Taking care of the soldiers.Journal of thoracic disease · 2018Article
- MicroRNA-26a targets MAPK6 to inhibit smooth muscle cell proliferation and vein graft neointimal hyperplasia.Scientific reports · 2017Article
- Eph-B4 mediates vein graft adaptation by regulation of endothelial nitric oxide synthase.Journal of vascular surgery · 2017Article
- Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Vein graft failure: from pathophysiology to clinical outcomes.Nature reviews. Cardiology · 2016Review
- Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector.Human gene therapy · 2015Article
- An emerging role for the miR-26 family in cardiovascular disease.Trends in cardiovascular medicine · 2014Review
- Vein graft adaptation and fistula maturation in the arterial environment.The Journal of surgical research · 2014Review
- Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA.Gene therapy · 2013Article
- miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation.European heart journal · 2013Article
- Gene therapy for the prevention of vein graft disease.Translational research : the journal of laboratory and clinical medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Autologous saphenous vein is commonly used as a conduit to bypass atherosclerotic lesions in coronary and femoral arteries. Despite the wide use of arterial conduits, which are less susceptible to complications and failure, as alternative conduits, the saphenous vein will continue to be used in coronary artery bypass grafting until acceptable alternative approaches are evaluated. Hence, preservation of vein graft patency is essential for the long-term success. Gene therapy is attractive in this setting as an ex-vivo technology to genetically manipulate the conduit before grafting. The use of safe and efficient vectors for delivery is a necessity as well as a strategy to improve patency in the long term. Here, we review the current clinical practice, the pathogenesis of bypass graft failure and adenovirus-mediated gene therapy strategies designed to improve late vein graft failure by modulation of smooth muscle cells in the vein wall.
Indexed as
Identifiers
22456326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.